Unraveling the Transcriptional Dynamics of NASH Pathogenesis Affecting Atherosclerosis

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jul 28

PMID 35897797

Authors

Anita M van den Hoek

Serdar Ozsezen

Martien P M Caspers

Arianne van Koppen

Roeland Hanemaaijer

Lars Verschuren

Affiliations

Soon will be listed here.

Abstract

The prevalence of non-alcoholic steatohepatitis (NASH) is rapidly increasing and associated with cardiovascular disease (CVD), the major cause of mortality in NASH patients. Although sharing common risk factors, the mechanisms by which NASH may directly contribute to the development to CVD remain poorly understood. The aim of this study is to gain insight into key molecular processes of NASH that drive atherosclerosis development. Thereto, a time-course study was performed in Ldlr-/-.Leiden mice fed a high-fat diet to induce NASH and atherosclerosis. The effects on NASH and atherosclerosis were assessed and transcriptome analysis was performed. Ldlr-/-.Leiden mice developed obesity, hyperlipidemia and insulin resistance, with steatosis and hepatic inflammation preceding atherosclerosis development. Transcriptome analysis revealed a time-dependent increase in pathways related to NASH and fibrosis followed by an increase in pro-atherogenic processes in the aorta. Gene regulatory network analysis identified specific liver regulators related to lipid metabolism (SC5D, LCAT and HMGCR), inflammation (IL1A) and fibrosis (PDGF, COL3A1), linked to a set of aorta target genes related to vascular inflammation (TNFA) and atherosclerosis signaling (CCL2 and FDFT1). The present study reveals pathogenic liver processes that precede atherosclerosis development and identifies hepatic key regulators driving the atherogenic pathways and regulators in the aorta.

Citing Articles

Searching for Hub Genes of Quince-Basil Co-Administration Against Atherosclerosis Using Bioinformatics Analysis and Experimental Validation.

Hailati S, Han M, Dilimulati D, Nueraihemaiti N, Baishan A, Aikebaier A Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598345 PMC: 11597616. DOI: 10.3390/ph17111433.

GEPREP: A comprehensive data atlas of RNA-seq-based gene expression profiles of exercise responses.

Sun L, Luan J, Wang J, Li X, Zhang W, Ji X J Sport Health Sci. 2024; 14:100992.

PMID: 39341494 PMC: 11863345. DOI: 10.1016/j.jshs.2024.100992.

Control of cardiometabolic risk factors and their association with carotid intima media thickness among patients with type 2 diabetes mellitus-single center experience in a developing country.

Weerarathna T, Lekamwasam S, Kodikara I, Wasana K, Fonseka L Turk J Med Sci. 2024; 54(3):545-554.

PMID: 39050007 PMC: 11265882. DOI: 10.55730/1300-0144.5821.

CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis.

Wu X, Yuan C, Pan J, Zhou Y, Pan X, Kang J Sci Rep. 2024; 14(1):16364.

PMID: 39013959 PMC: 11252365. DOI: 10.1038/s41598-024-66287-4.

Integrated multi-omics and machine learning approach reveals lipid metabolic biomarkers and signaling in age-related meibomian gland dysfunction.

Cai Y, Zhang S, Chen L, Fu Y Comput Struct Biotechnol J. 2023; 21:4215-4227.

PMID: 37675286 PMC: 10480060. DOI: 10.1016/j.csbj.2023.08.026.

References

DAgostino Sr R, Vasan R, Pencina M, Wolf P, Cobain M, Massaro J . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117(6):743-53. DOI: 10.1161/CIRCULATIONAHA.107.699579. View

van Koppen A, Verschuren L, van den Hoek A, Verheij J, Morrison M, Li K . Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model. Cell Mol Gastroenterol Hepatol. 2017; 5(1):83-98.e10. PMC: 5738456. DOI: 10.1016/j.jcmgh.2017.10.001. View

Luque-Sierra A, Alvarez-Amor L, Kleemann R, Martin F, Varela L . Extra-Virgin Olive Oil with Natural Phenolic Content Exerts an Anti-Inflammatory Effect in Adipose Tissue and Attenuates the Severity of Atherosclerotic Lesions in Ldlr-/-.Leiden Mice. Mol Nutr Food Res. 2018; 62(13):e1800295. DOI: 10.1002/mnfr.201800295. View

Angulo P, Kleiner D, Dam-Larsen S, Adams L, Bjornsson E, Charatcharoenwitthaya P . Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015; 149(2):389-97.e10. PMC: 4516664. DOI: 10.1053/j.gastro.2015.04.043. View

van den Hoek A, Verschuren L, Worms N, van Nieuwkoop A, de Ruiter C, Attema J . A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology. Cells. 2020; 9(9). PMC: 7565967. DOI: 10.3390/cells9092014. View

Salic K, Kleemann R, Wilkins-Port C, McNulty J, Verschuren L, Palmer M . Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice. PLoS One. 2019; 14(6):e0218459. PMC: 6590809. DOI: 10.1371/journal.pone.0218459. View

Mellinger J, Pencina K, Massaro J, Hoffmann U, Seshadri S, Fox C . Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study. J Hepatol. 2015; 63(2):470-6. PMC: 5282653. DOI: 10.1016/j.jhep.2015.02.045. View

Polimeni L, Ben M, Baratta F, Perri L, Albanese F, Pastori D . Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol. 2015; 7(10):1325-36. PMC: 4450196. DOI: 10.4254/wjh.v7.i10.1325. View

Huynh-Thu V, Geurts P . dynGENIE3: dynamical GENIE3 for the inference of gene networks from time series expression data. Sci Rep. 2018; 8(1):3384. PMC: 5821733. DOI: 10.1038/s41598-018-21715-0. View

10.

Pelgrim C, Franx B, Snabel J, Kleemann R, Arnoldussen I, Kiliaan A . Butyrate Reduces HFD-Induced Adipocyte Hypertrophy and Metabolic Risk Factors in Obese LDLr-/-.Leiden Mice. Nutrients. 2017; 9(7). PMC: 5537829. DOI: 10.3390/nu9070714. View

11.

Delsing D, Offerman E, van Duyvenvoorde W, van der Boom H, de Wit E, Gijbels M . Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation. 2001; 103(13):1778-86. DOI: 10.1161/01.cir.103.13.1778. View

12.

Bornfeldt K, Tabas I . Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011; 14(5):575-85. PMC: 3217209. DOI: 10.1016/j.cmet.2011.07.015. View

13.

van den Hoek A, de Jong J, Worms N, van Nieuwkoop A, Voskuilen M, Menke A . Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk. Metabolism. 2021; 124:154873. DOI: 10.1016/j.metabol.2021.154873. View

14.

Martinez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Minchole I, Bizkarguenaga M . Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology. 2022; 76(4):1121-1134. PMC: 9790568. DOI: 10.1002/hep.32427. View

15.

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

16.

Teufel A, Itzel T, Erhart W, Brosch M, Wang X, Kim Y . Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients. Gastroenterology. 2016; 151(3):513-525.e0. DOI: 10.1053/j.gastro.2016.05.051. View

17.

Morrison M, Mulder P, Salic K, Verheij J, Liang W, van Duyvenvoorde W . Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice. Int J Obes (Lond). 2016; 40(9):1416-23. PMC: 5022108. DOI: 10.1038/ijo.2016.74. View

18.

Wang Y, Niimi M, Nishijima K, Waqar A, Yu Y, Koike T . Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits. Arterioscler Thromb Vasc Biol. 2012; 33(2):224-31. PMC: 3673010. DOI: 10.1161/ATVBAHA.112.300445. View

19.

Schoemaker M, Kleemann R, Morrison M, Verheij J, Salic K, Van Tol E . A casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in LDLr-/-.Leiden mice. PLoS One. 2017; 12(7):e0180648. PMC: 5498059. DOI: 10.1371/journal.pone.0180648. View

20.

Guo M, Liu Z, Xu Y, Ma P, Huang W, Gao M . Spontaneous Atherosclerosis in Aged LCAT-Deficient Hamsters With Enhanced Oxidative Stress-Brief Report. Arterioscler Thromb Vasc Biol. 2020; 40(12):2829-2836. DOI: 10.1161/ATVBAHA.120.315265. View